Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci
Creators
- 1. Department of Radiation Oncology, University of Würzburg, Josef-Schneider-Str. 11, Würzburg D-97080 (Germany)
- 2. Department of Radiation Oncology, University of Erlangen-Nürnberg, Universitätsstraße 27, Erlangen, D-91054 (Germany)
Description
High expression of constitutive histone γ-H2AX, a sensitive marker of DNA damage, might be indicative of defective DNA repair pathway or genomic instability. 53BP1 (p53-binding protein 1) is a conserved checkpoint protein with properties of a DNA double-strand breaks sensor. This study explores the relationship between the clinical radiosensitivity of tumor patients and the expression/induction of γ-H2AX and 53BP1 in vitro. Using immunostaining, we assessed spontaneous and radiation-induced foci of γ-H2AX and 53 BP1 in peripheral blood mononuclear cells derived from unselected breast cancer (BC) patients (n=57) undergoing radiotherapy (RT). Cells from apparently healthy donors (n=12) served as references. Non-irradiated cells from controls and unselected BC patients exhibited similar baseline levels of DNA damage assessed by γ-H2AX and 53BP1 foci. At the same time, the γ-H2AX assay of in vitro irradiated cells revealed significant differences between the control group and the group of unselected BC patients with respect to the initial (0.5 Gy, 30 min) and residual (2 Gy, 24 h post-radiation) DNA damage. The numbers of 53BP1 foci analyzed in 35 BC patients were significantly higher than in controls only in case of residual DNA damage. A weak correlation was found between residual foci of both proteins tested. In addition, cells from cancer patients with an adverse acute skin reaction (grade 3) to RT showed significantly increased radiation-induced γ-H2AX foci and their protracted disappearance compared to the group of BC patients with normal skin reaction (grade 0–1). The mean number of γ-H2AX foci after 5 clinical fractions was significantly higher than that before RT, especially in clinically radiosensitive patients. The γ-H2AX assay may have potential for screening individual radiosensitivity of breast cancer patients.
Availability note (English)
Available from http://dx.doi.org/10.1186/1748-717X-8-98; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653697Additional details
Identifiers
Publishing Information
- Journal Title
- Radiation Oncology (Online)
- Journal Volume
- 8
- Journal Page Range
- p. 98
- ISSN
- 1748-717X
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47065762
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- DNA REPAIR; GY RANGE 01-10; IN VITRO; MAMMARY GLANDS; NEOPLASMS; PATIENTS; PROTEINS; RADIOSENSITIVITY; RADIOTHERAPY; STRAND BREAKS
- Descriptors DEC
- ABSORBED DOSE RANGE; BIOLOGICAL RECOVERY; BIOLOGICAL REPAIR; BODY; DISEASES; DNA DAMAGES; GLANDS; GY RANGE; MEDICINE; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; REPAIR; SENSITIVITY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2013 Djuzenova et al.
- Notes
- PMCID: PMC3653697; PUBLISHER-ID: 1748-717X-8-98; PMID: 23617930; OAI: oai:pubmedcentral.nih.gov:3653697; licensee BioMed Central Ltd.